The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Neoadjuvant capecitabine, oxliplatin, and bevacizumab (CAPOX-B) in intermediate-risk rectal cancer (RC) patients defined by magnetic resonance (MR): GEMCAD 0801 trial.
Carlos Fernandez-Martos
No relevant relationships to disclose
Rafael Estevan
No relevant relationships to disclose
Antonia Salud
No relevant relationships to disclose
Carles Pericay
No relevant relationships to disclose
Manuel Gallen
No relevant relationships to disclose
Enrique Sierra
No relevant relationships to disclose
Javier Serra
No relevant relationships to disclose
Miguel Pera
No relevant relationships to disclose
Juan Maurel
No relevant relationships to disclose
Salvadora Delgado
No relevant relationships to disclose
M. José Safont
No relevant relationships to disclose
Jose Vicente Roig
No relevant relationships to disclose
Jorge Aparicio
No relevant relationships to disclose
Jaime Feliu
No relevant relationships to disclose
Damian Garcia
No relevant relationships to disclose
Ruth Vera
No relevant relationships to disclose
Javier Suarez
No relevant relationships to disclose
Vicente Alonso
No relevant relationships to disclose
Marta Martin-Richard
No relevant relationships to disclose
Gina Brown
No relevant relationships to disclose